-
31.发明授权公开(公告)号：US10934333B2
公开(公告)日：2021-03-02
申请号：US16915745
申请日：2020-06-29
Applicant: Immatics Biotechnologies GmbH
Inventor： Andrea Mahr , Toni Weinschenk , Helen Hoerzer , Oliver Schoor , Jens Fritsche , Harpreet Singh
IPC: C07K14/47 , A61K35/17 , C07K14/74 , A61K39/00 , C12N15/115 , C07K7/08 , C07K7/06 , C07K16/28 , C12N5/0783 , C07K16/30 , C12P21/02 , C12Q1/6881 , G01N33/569 , C07K14/82 , C07K16/32 , C12Q1/6886 , G01N33/574 , C07K14/705 , C07K16/18 , A61K38/00 , A61K35/12
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
32.发明授权公开(公告)号：US10533041B2
公开(公告)日：2020-01-14
申请号：US16281790
申请日：2019-02-21
Applicant: Immatics Biotechnologies GmbH
Inventor： Andrea Mahr , Toni Weinschenk , Helen Hoerzer , Oliver Schoor , Jens Fritsche , Harpreet Singh
IPC: A61K39/00 , C07K14/47 , C07K14/74 , C12N15/115 , C07K7/08 , C07K7/06 , C07K16/28 , C12N5/0783 , A61K35/17 , C07K16/30 , C12P21/02 , C12Q1/6881 , G01N33/569 , C07K14/82 , C07K16/32 , C12Q1/6886 , G01N33/574 , C07K14/705 , C07K16/18 , A61K38/00 , A61K35/12
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
33.发明申请公开(公告)号：US20190092824A1
公开(公告)日：2019-03-28
申请号：US16212178
申请日：2018-12-06
Applicant: IMMATICS BIOTECHNOLOGIES GMBH
Inventor： Andrea MAHR , Toni Weinschenk , Helen Hoerzer , Oliver Schoor , Jens Fritsche , Harpreet Singh
IPC: C07K14/47 , G01N33/574 , C07K16/18 , C12P21/02 , C07K16/30 , A61K35/17 , C07K14/82 , C07K14/705 , C07K14/74 , A61K39/00 , C07K7/06 , C12N5/0783 , C12N15/115 , C07K7/08 , C07K16/28 , C12Q1/6886 , G01N33/569 , C07K16/32 , C12Q1/6881 , A61K38/00 , A61K35/12
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
34.发明授权公开(公告)号：US10239925B2
公开(公告)日：2019-03-26
申请号：US16101081
申请日：2018-08-10
Applicant: IMMATICS BIOTECHNOLOGIES GMBH
Inventor： Andrea Mahr , Toni Weinschenk , Helen Hoerzer , Oliver Schoor , Jens Fritsche , Harpreet Singh
IPC: A61K39/395 , C07K14/47 , C07K14/82 , C07K14/705 , A61K35/17 , G01N33/569 , C12P21/02 , C07K16/30 , C12Q1/6881 , C07K16/32 , G01N33/574 , C12Q1/6886 , C07K16/28 , C07K16/18 , C07K14/74 , A61K39/00 , C12N15/115 , C07K7/08 , C07K7/06 , C12N5/0783 , A61K35/12 , A61K38/00
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号：US10227388B2
公开(公告)日：2019-03-12
申请号：US15199182
申请日：2016-06-30
Applicant: immatics biotechnologies GmbH
Inventor： Andrea Mahr , Toni Weinschenk , Helen Hoerzer , Oliver Schoor , Jens Fritsche , Harpreet Singh
IPC: C07K14/47 , C07K14/74 , A61K39/00 , C12N15/115 , C07K7/08 , C07K7/06 , C07K16/28 , C12N5/0783 , A61K35/17 , C07K16/30 , C12P21/02 , C12Q1/6881 , G01N33/569 , C07K14/82 , C07K16/32 , C12Q1/6886 , G01N33/574 , C07K14/705 , C07K16/18 , A61K38/00 , A61K35/12
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
Patent Agency Ranking
36.发明授权公开(公告)号：US10213499B2
公开(公告)日：2019-02-26
申请号：US16065681
申请日：2016-11-29
Applicant: immatics biotechnologies GmbH
Inventor： Andrea Mahr , Toni Weinschenk , Helen Hoerzer , Oliver Schoor , Jens Fritsche , Harpreet Singh
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
37.发明授权公开(公告)号：US10166278B2
公开(公告)日：2019-01-01
申请号：US16024164
申请日：2018-06-29
Applicant: immatics biotechnologies GmbH
Inventor： Andrea Mahr , Toni Weinschenk , Helen Hoerzer , Oliver Schoor , Jens Fritsche , Harpreet Singh
IPC: A61K35/17 , A61K39/00 , A61K38/17 , C07K7/06 , C07K14/47 , C07K14/725 , C12N15/115 , A61P35/02 , C07K16/28 , A61K38/08
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
38.发明授权公开(公告)号：US10143732B2
公开(公告)日：2018-12-04
申请号：US16024133
申请日：2018-06-29
Applicant: immatics biotechnologies GmbH
Inventor： Andrea Mahr , Toni Weinschenk , Helen Hoerzer , Oliver Schoor , Jens Fritsche , Harpreet Singh
IPC: A61K35/17 , A61K39/00 , A61K38/17 , C07K7/06 , C07K14/47 , C07K14/725 , C12N15/115 , A61P35/02 , C07K16/28 , A61K39/39 , A61K38/08 , A61K38/00
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
39.发明授权公开(公告)号：US10000539B2
公开(公告)日：2018-06-19
申请号：US15198471
申请日：2016-06-30
Applicant: immatics biotechnologies GmbH
Inventor： Andrea Mahr , Toni Weinschenk , Helen Hoerzer , Oliver Schoor , Jens Fritsche , Harpreet Singh
IPC: A61K39/00 , C07K14/47 , C07K14/74 , C12N15/115 , C07K7/08 , C07K7/06 , C07K16/28 , C12N5/0783 , A61K35/17 , C07K16/30 , C12P21/02 , C12Q1/68 , G01N33/569 , C07K14/82 , C07K16/32 , G01N33/574 , C07K14/705 , C07K16/18 , A61K38/00 , A61K35/12
CPC classification number: C07K14/4748 , A61K35/17 , A61K38/00 , A61K39/00 , A61K39/0011 , A61K2035/124 , A61K2039/5158 , C07K7/06 , C07K7/08 , C07K14/4705 , C07K14/4738 , C07K14/705 , C07K14/70539 , C07K14/82 , C07K16/18 , C07K16/28 , C07K16/2833 , C07K16/30 , C07K16/3015 , C07K16/3023 , C07K16/303 , C07K16/3038 , C07K16/3046 , C07K16/3053 , C07K16/3069 , C07K16/32 , C07K2317/24 , C07K2317/31 , C07K2317/34 , C07K2319/00 , C07K2319/40 , C12N5/0636 , C12N15/115 , C12N2310/16 , C12N2320/30 , C12N2501/50 , C12N2501/998 , C12P21/02 , C12Q1/6881 , C12Q1/6886 , C12Q2600/158 , G01N33/56977 , G01N33/57449 , G01N33/57492 , G01N2333/70539
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
40.发明申请公开(公告)号：US20180066032A1
公开(公告)日：2018-03-08
申请号：US15815644
申请日：2017-11-16
Applicant: IMMATICS BIOTECHNOLOGIES GMBH
Inventor： Andrea Mahr , Toni Weinschenk , Helen Hoerzer , Oliver Schoor , Jens Fritsche , Harpreet Singh
IPC: C07K14/47 , G01N33/574 , A61K39/00 , C07K7/06 , C07K7/08 , C07K14/705 , C07K14/74 , C07K14/82 , C07K16/18 , C07K16/28 , C07K16/30 , G01N33/569 , C12Q1/68 , C12P21/02 , C12N15/115 , C12N5/0783 , C07K16/32 , A61K38/00 , A61K35/12
CPC classification number: C07K14/4748 , A61K35/17 , A61K38/00 , A61K39/00 , A61K39/0011 , A61K2035/124 , A61K2039/5158 , C07K7/06 , C07K7/08 , C07K14/4705 , C07K14/4738 , C07K14/705 , C07K14/70539 , C07K14/82 , C07K16/18 , C07K16/28 , C07K16/2833 , C07K16/30 , C07K16/3015 , C07K16/3023 , C07K16/303 , C07K16/3038 , C07K16/3046 , C07K16/3053 , C07K16/3069 , C07K16/32 , C07K2317/24 , C07K2317/31 , C07K2317/34 , C07K2319/00 , C07K2319/40 , C12N5/0636 , C12N15/115 , C12N2310/16 , C12N2320/30 , C12N2501/50 , C12N2501/998 , C12P21/02 , C12Q1/6881 , C12Q1/6886 , C12Q2600/158 , G01N33/56977 , G01N33/57449 , G01N33/57492 , G01N2333/70539
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
-
-
-
-
-
-
-
-
Search Results
40
records
(took 0.097 seconds)
